IP Library Granted Patent US 7,125,903
Granted Patent B1
US 7,125,903 · App. 10/088,250 · Granted Oct 24, 2006

Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,903
App. No.
10/088,250
Granted
Oct 24, 2006
Kind
B1
Abstract

The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D 4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D 4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

Claims (89)

1. A compound of Formula I:

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH 3 ) or O;

R 1 is OH or C 1-6 alkoxy;

R 2 is H or C 1-6 alkyl;

R 3 is (CH 2 ) n Q, CH 2 CH(OH)Q, CH(CH 3 )Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl or furanyl and

Q is optionally substituted with one or two moieties independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, S(O)H 2 NH 2 , trifluormethyl, or cyano, and

n is 1 or 2; and

R 4 is H or C 1-6 alkyl.

2. A compound according to claim 1 wherein

Q is thienyl.

3. The compound according to claim 2 which is (2R)-2-methyl-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[thienophen-2-ylmethyl)-amino-propan-2-ol.

4. The compound according to claim 2 which is (2S)-1-(2-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.

5. The compound according to claim 2 which is (2S)-1-(3-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-d]isoxazol-3-yl-phenoxy]propan-2-ol.

6. A compound according to claim 2 wherein

R 1 is OH;

R 2 is H;

R 3 is (CH 2 ) n Q; and

n is 1.

7. A compound according to claim 6 wherein Q is thienyl.

8. The compound according to claim 7 which is (2R)-1-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)-amino]-propan-2-ol.

9. The compound of claim 7 which is (2R)-1-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)-amino]-propan-2-ol.

10. The compound of claim 7 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)amino]propan-2-ol.

11. The compound of claim 7 which is (2R)-1-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)amino]propan-2-ol.

12. A compound according to claim 1 wherein Q is furanyl.

13. The compound of claim 12 which is (2R)-1-[(furan-2-ylmethyl)-amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

14. The compound of claim 12 which is (2R)-1-[(furan-2-ylmethyl)amino]-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

15. The compound of claim 12 which is (2R)-1-[(furan-2-ylmethyl)-amino]-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.

16. The compound of claim 12 which is (2S)-1-[(furan-2-ylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.

17. A compound according to claim 1 wherein R 3 is indanyl.

18. The compound of claim 17 which is (2R)-1-(indan-1-ylamino)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

19. The compound of claim 17 which is (2R)-1-(indan-2-ylamino)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

20. A compound according to claim 1 , wherein R 3 is adamantyl.

21. The compound of claim 20 which is (2R)-1-(adamantan-1-ylamino)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

22. A compound according to claim 1 , wherein R 3 is 1,2,3,4-tetrahydronaphthyl.

23. The compound of claim 22 which is (2R)-1-(1,2,3,4-tetrahydronaphthalen-1-ylamino)-3-[3-thieno[2,3-d]isoxazol-3-yl)phenoxy]propan-2-ol.

24. A composition comprising a compound according to claim 1 in admixture with an inert carrier.

25. The composition according to claim 24 wherein said inert carrier is a pharmaceutical carrier.

26. A method of making a compound of formula I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH 3 ) or O;

R 1 is OH or C 1-6 alkoxy;

R 2 is H or C 1-6 alkyl;

R 3 is (CH 2 ) n Q, CH 2 CH(OH)Q, CH(CH 3 )Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl or furanyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, S(O) 2 NH 2 , trifluoromethyl, or cyano, and

n is 1 or 2; and

R 4 is H or C 1-6 alkyl;

comprising the step of coupling a reagent of formula II

wherein X and R 2 are as defined in formula I;

with a reagent of formula III

wherein R 3 and R 4 are as defined in formula I;

to provide the compound of formula I.

27. A method of making a compound of formula I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH 3 ) or O;

R 1 is OH or C 1-6 alkoxy;

R 2 is H or C 1-6 alkyl;

R 3 is (CH 2 ) n Q, CH 2 CH(OH)Q, CH(CH 3 )Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl or furanyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, S(O) 2 NH 2 , trifluoromethyl, or cyano, and

n is 1 or 2; and

R 4 is H or C 1-6 alkyl;

comprising the step of coupling a compound of formula II

wherein X and R 2 are as defined in formula I; and

R 5 is CH 3 , CF 3 , F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene;

with a reagent of formula m

wherein R 3 and R 4 are as defined in formula I;

to provide the compound of formula I.

28. A method of making a compound of formula I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is N(CH 3 ) or O;

R 1 is OH or C 1-6 alkoxy;

R 2 is H or C 1-6 alkyl;

R 3 is (CH 2 ) n Q, CH 2 CH(OH)Q, CH(CH 3 )Q, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl or furanyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, S(O) 2 NH 2 , trifluoromethyl, or cyano, and

n is 1 or 2; and

R 4 is H or C 1-6 alkyl;

comprising the step of coupling a reagent of formula II

wherein X is as defined in formula I;

with a reagent of formula III

wherein R 2 , R 3 , and R 4 are as defined in formula I;

to provide the compound of formula I.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2010
From: AVENTIS HOLDINGS INC.
To: AVENTISUB II INC.
Reel/Frame 024006/0487 →
CHANGE OF NAME Recorded Nov 29, 2007
From: HMR PHARMA INC.
To: AVENTIS HOLDINGS INC.
Reel/Frame 020174/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2007
From: AVENTIS PHARMACEUTICALS INC.
To: HMR PHARMA INC.
Reel/Frame 020119/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2005
From: FINK, DAVID M.; LEE, GEORGE E.; FREED, BRIAN S.; MERRIMAN, GREGORY H.; HRIB, NICHOLAS J.; KOSLEY, JR., RAYMOND W.; RAUCKMAN, BARBARA S.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 016103/0148 →